EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018–23

Porntip Paopang, Pongsathorn Sangprasert, Daniel Golparian, Natnaree Girdthep iD, Nutchaya Jintana, Supawadee Sonnak, Padchara Sangsuk, Thewarkrith Bunpan, Magnus Unemo iD, Rossaphorn Kittiyaowamarn iD

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.08.2026. Verfasst von Porntip Paopang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health, Nonthaburi, Thailand. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents, Gonorrhea, Drug Resistance, Bacterial. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bangrak STIs Center, Bangkok, Thailand, Örebro County Council Research Committee and Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global public health concern, particularly due to increasing resistance to the last remaining monotherapy, ceftriaxone, in several Asian countries. We examined the AMR of gonococcal isolates obtained at the Bangrak STIs Center, Bangkok, Thailand in 2018–23, and used WGS on isolates resistant to ceftriaxone, cefixime and/or azithromycin.

Methods

Genital and extragenital swabs from males, females and transgender women were cultured. Etest (five antimicrobials) and EUCAST breakpoints (v16.0), or disc diffusion method (ciprofloxacin) were used to determine AMR. WGS was performed using Illumina NextSeq 550.

Results

In 2018–23, 765 gonococcal isolates from 739 patients were cultured. Resistance to ceftriaxone, cefixime, azithromycin, tetracycline and ciprofloxacin was 0.5%, 0.8%, 1.7%, 83.7% and 95.7%, respectively. Ceftriaxone-resistant isolates, all resistant also to cefixime, were first detected in 2023 (n = 3, 1.2%). Additional cefixime-resistant isolates were found in 2022 (n = 2, 1.4%). Azithromycin-resistant isolates first emerged in 2020 (n = 1, 0.9%) and increased to nine (3.7%) isolates in 2023. All ceftriaxone-resistant isolates contained penA-60.001, but cefixime resistance was additionally caused by penA-34.019 and penA-10.001. All azithromycin-resistant isolates had 23S rRNA mutations and/or mosaic/semi-mosaic MtrD (subunit of the MtrCDE efflux pump).

Conclusions

Resistance to ceftriaxone, cefixime and azithromycin has emerged in gonococcal strains circulating in Bangkok, Thailand, and resistance appears to be increasing. Resistance to these last options for monotherapy or dual therapy emphasize the need for strengthened national culture-based and genomic surveillance to prevent the spread of MDR and XDR strains in Thailand and globally, and implementation of the novel oral treatments, i.e. zoliflodacin and gepotidacin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeAnti-Bacterial AgentsGonorrheaDrug Resistance, BacterialDrug Resistance, Multiple, BacterialThailandHumansFemaleWhole Genome SequencingMaleMicrobial Sensitivity TestsCefiximeThird Generation CephalosporinsAzithromycinCeftriaxone

Substanzen

Anti-Bacterial AgentsCefiximeThird Generation CephalosporinsAzithromycinCeftriaxone

Autor:innen und Institutionen

  • Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Thailand Ministry of Public Health, Nonthaburi, Thailand.
  • WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Department of Medical Technology and Clinical Pathology, Vachira Phuket Hospital, Phuket, Thailand.
  • Institute for Global Health, University College London, London, UK.

ORCID-Profile: Natnaree Girdthep, Magnus Unemo, Rossaphorn Kittiyaowamarn

Förderung

  • Bangrak STIs Center, Bangkok, Thailand
  • Örebro County Council Research Committee and Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden

Zitieren

APA

Paopang, P., Sangprasert, P., Golparian, D., Girdthep, N., Jintana, N., Sonnak, S., Sangsuk, P., Bunpan, T., Unemo, M., & Kittiyaowamarn, R. (2026). Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018–23. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag260

Vancouver

Paopang P, Sangprasert P, Golparian D, Girdthep N, Jintana N, Sonnak S, et al. Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018–23. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag260

BibTeX
@article{Paopang2026,
  author = {Paopang, Porntip and Sangprasert, Pongsathorn and Golparian, Daniel and Girdthep, Natnaree and Jintana, Nutchaya and Sonnak, Supawadee and Sangsuk, Padchara and Bunpan, Thewarkrith and Unemo, Magnus and Kittiyaowamarn, Rossaphorn},
  title = {Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018–23},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag260}
}
Kostenlos starten →